HDAC6 and glioblastoma: In summary, our data reveal high levels of HDAC6 in human GBM tissues and patient-derived GSCs, which correlate with lower patient survival, and describe the new small-molecule inhibitor of HDAC6 JOC1 that inhibits GBM cell growth and GSC activity and causes programmed cell death in vitro.